Amgen's long-acting experimental obesity drug MariTide needs to be given at a low starting dose to limit side effects like vomiting, according to mid-stage trial results presented at a medical meeting ...

Semaglutide improved time spent in glycemic range, time below rate and reduced body weight with low rates of hypoglycemia ...

Shares of Novo Nordisk (NYSE: NVO) are tumbling on Monday, down 5.6% as of 2:11 p.m. ET. The drop comes as the S&P 500 ...

Once-monthly maridebart cafraglutide resulted to significant weight loss at 1 year among adults with obesity, regardless of ...

Amycretin, a new weight-loss treatment from Novo Nordisk, combines two hunger hormones, helping participants lose nearly ...

Amgen's experimental drug MariTide shows potential for significant weight loss in obese patients, despite notable side ...

For adults with obesity or overweight without diabetes, the novel cyclic adenosine monophosphate-biased glucagon-like peptide ...

CHICAGO -- Semaglutide (Ozempic) reduced glucose levels and weight among patients with type 1 diabetes and obesity, a ...

Historic changes are afoot for pharma as China gains ground on U.S. production. The pharma industry is projected to see ...

A new drug called amycretin has shown it can help reduce body weight in two early-phase clinical trials. The drug, which ...

Novo Nordisk has ended its partnership with Hims & Hers Health Inc., citing “deceptive marketing” and the selling of ...

Amgen is expanding development plans for its weight-loss drug MariTide to study its use for heart disease and sleep apnea.